Article
No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors.
Pharmacogenetics - 1 Oct 2002
Weber Artur-Aron, Jacobs Collin, Meila Dan, Weber Stephanie, Zotz Rainer B, Scharf Rüdiger E, Kelm Malte, Strauer Bodo E, Schrör Karsten
Abstract excerpt
This study investigated the hypothesis that the human platelet antigen-1 (HPA-1) polymorphism may influence the antiplatelet effects of glycoprotein (GP)IIb/IIIa inhibitors. Adenosine diphosphate (30 micro mol)-induced fibrinogen binding was measured by flow cytometry. Abciximab (0.03-3 micro g/ml), tirofiban (0.3-30 nmol/l) or eptifibatide (0.01-1 micro g/ml) were incubated for 15 min with the samples prior to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
